Research programme: targeted alpha-particle radiotherapeutics - Affibody/AlgetaAlternative Names: 227Th-Affibody® molecule radioimmunoconjugate; Radiotherapeutics - Affibody/Algeta; Thorium-227-Affibody® molecule radioimmunoconjugate
Latest Information Update: 11 Mar 2014
At a glance
- Originator Affibody; Algeta
- Class Proteins; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer